Investigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients

Table 3

The comparisons of characteristics among the VDR genotypes in acromegaly patients.

Genotypes

Age onset; (years)

GH (ng/mL)

IGF1 (ng/mL)

IGF1 (% ULN)

Tumor size before treatment (, %)

Remission (, %)

25(OH)D3; (nmol/L)

Before treatment

After treatment

Before treatment

After treatment

Before treatment

After treatment

<1 cm

≥1 cm

Controlled

Uncontrolled

ApaI

AA

39.5 ± 2.6

21.4 ± 5

1.15 ± 0.3

885.4 ± 78.6

248.4 ± 30

321.7 ± 30.6

103.5 ± 12.3

3 (37.5)

14 (38.9)

12 (33.3)

3 (33.3)

6.5 ± 2.5

Aa

40.4 ± 3.2

18 ± 4.3

1.1 ± 0.2

896.4 ± 100.7

228 ± 33.2

335.7 ± 33.6

101.7 ± 18.4

4 (50)

18 (50)

19 (52.8)

4 (44.4)

3.4 ± 0.9

aa

36.1 ± 5.5

11.1 ± 4.1

2.1 ± 1

829.6 ± 89.2

226.4 ± 59.3

335.4 ± 63.6

92.1 ± 18.6

1 (12.5)

4 (11.1)

5 (13.9)

2 (22.2)

10 ± 2.2

FokI

FF

39.7 ± 3

12.5 ± 4.1

1.6 ± 0.3

907.5 ± 93.1

249.5 ± 39.9

344.2 ± 36.8

106.8 ± 20.1

3 (37.5)

10 (27.8)

9 (25)

4 (44.4)

5.4 ± 1.6

Ff

39.2 ± 2.6

20.7 ± 4.3

1.3 ± 0.3

869.3 ± 79.6

245 ± 29.1^a

312.9 ± 27.8

104.6 ± 14.2

5 (62.5)

22 (61.1)

22 (61.1)

5 (55.6)

4.6 ± 1.1

ff

40.2 ± 8.5

24.2 ± 8.1

0.4 ± 0.1

857.3 ± 185.4

139.6 ± 15.6

377.5 ± 74.8

66.3 ± 12.3

0

4 (11.1)

5 (13.9)

0

11.5 ± 8.8

TaqI

TT

37.8 ± 3.1

11.4 ± 3.1

0.8 ± 0.3

869.3 ± 108.5

229.5 ± 25.3

317.5 ± 36.6

91.9 ± 9.3

3 (37.5)

12 (33.3)

14 (38.9)

2 (33.3)

2.1 ± 0.8

Tt

39.6 ± 2.7

24.3 ± 4.4

1.5 ± 0.3

912.7 ± 74.9

248.2 ± 3

335.9 ± 28.2

110.6 ± 17.8

4 (50)

21 (58.3)

19 (52.8)

6 (66.7)

7.4 ± 1.8

tt

46.5 ± 4.7

8.7 ± 3

1.97 ± 0.7

756.8 ± 141

149.3 ± 22.3

330.6 ± 75

73.3 ± 13.6

1 (12.5)

3 (8.3)

3 (8.3)

0

6.8 ± 3.9

Data are shown as mean ± standard error. IGF1 (%ULN): IGF1/upper limit of normal (age-matched) 100.
^aFf versus ff (Mann-Whitney test).